Back to results
US 2024/0366591 A1Published application
Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
AssigneeAuspex Pharmaceuticals, Inc.
InventorsAndreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
Life of this patent
Estimating the term…
Abstract
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Claims12
A solid deutetrabenazine oral dosage form comprising deutetrabenazine and a poly(ethylene oxide) polymer.
Dependencies are inferred from the claim text.